ArticlePloS one2026
Allostatic load and progression of cardio-renal multimorbidity: A UK biobank study.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Psychosocial factors in patients who miss hemodialysis sessions: a single-center retrospective review.Renal failure · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardio-renal multimorbidity (CRM), the coexistence of cardiovascular disease (CVD) and chronic kidney disease (CKD), imposes a significant healthcare burden. Allostatic load (AL), indicating cumulative physiological dysregulation from chronic stress, may be a modifiable risk factor for CRM.
methodsThis study included 396,927 participants with a median follow-up of 13.67 years. AL was assessed via 10 biomarkers. Multistate models were used to analyze transitions from health to first cardio-renal disease (FCRD), to CRM, and to death.
resultsHigher AL was significantly associated with increased risks of progression from health to FCRD, to CRM, and to death. The transition from FCRD to CRM was most affected by high AL. AL also had a stronger association with the transition from health to CKD than to CVD. Stratified analyses showed more pronounced associations in younger participants, those with higher socioeconomic status (SES), and unhealthy diets.
conclusionAL is a significant upstream factor in CRM development and progression. Early identification of individuals with high AL could aid in risk assessment and prevention strategies for CRM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.